Skip to content

Methadone and Hydromorphone For Spinal Surgery

Methadone and Hydromorphone For Spinal Surgery

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02107339
Enrollment
120
Registered
2014-04-08
Start date
2014-03-31
Completion date
2017-09-30
Last updated
2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Postoperative Pain, Chronic Persistent Surgical Pain, Hydromorphone Use, Patient Satisfaction

Keywords

methadone, hydromorphone, acute postoperative pain, chronic persistent surgical pain

Brief summary

Patients undergoing major spinal surgery continue to experience moderate-to-severe pain during the first 2-3 days following the operative procedure. Pain complicates the recovery process, despite the routine practice of using potent opioid analgesics. The primary reason that pain is poorly controlled in patients undergoing major surgery is that most commonly-used opioids only produce analgesia for 2-4 hours. The intermittent use of these drugs results in periods of time when a patient will experience discomfort (at which time a nurse administers more drug or the button on a patient-controlled analgesic (PCA) system is pressed to deliver more medication). The use of a long-acting opioid may be advantageous in the perioperative setting. Methadone is an opioid that has a median duration of analgesia of 24-36 hours. Therefore, a single dose administered in the operating room may reduce the need for pain medication and improve pain control for the first few postoperative days. The aim of this randomized clinical trial is to examine the effect of methadone (compared to hydromorphone) on postoperative pain management in patients undergoing major spine surgery

Detailed description

Patients: 100 patients (ages 18-80) will be enrolled in this clinical trial. All patients presenting for elective posterior lumbar or thoracic spinal fusion surgery will be eligible for enrollment. Patients will be randomized to receive either methadone or hydromorphone on the basis of a computer generated random number table. Patients in each group will receive standard clinical intraoperative doses of either methadone (0.2 mg/kg) or hydromorphone (2 mg). An analysis of patients undergoing posterior lumbar fusion surgery at Evanston Hospital revealed that patients received, on average, approximately 2 mg of hydromorphone intraoperatively. The most commonly used doses of methadone administered in clinical studies have been either 0.2 mg/kg or a dose of 20 mg. Furthermore, these doses also represent dosages which appear to be approximately equipotent. Study medications will be prepared by the pharmacy, and all clinicians will be blinded to group assignment. Two syringes will be prepared for each patient, one which contains the study drug (either methadone 0.2 mg/kg or hydromorphone 2 mg), and the other containing the placebo (saline). If the patient is randomized to the methadone group, a 3 cc syringe containing 0.2 mg/kg of methadone and saline (total volume 3 cc) will be prepared, as well as a 10 cc syringe containing 10 cc of saline (placebo). If the patient is randomized to the hydromorphone group, a 3 cc syringe containing 3 cc of saline (placebo) will be prepared, as well as a 10 cc syringe containing 2 mg of hydromorphone with 9 cc of saline (total volume 10 cc). At induction of anesthesia, the 3 cc syringe containing either 0.2 mg/kg of methadone or placebo will be given over 5 seconds. At the conclusion of surgery, the 10 cc syringe of either hydromorphone or placebo will be titrated slowly per clinician's preference. The administration of all other anesthetic agents will be standardized and reflect the usual practices of anesthesiologists at Evanston Hospital (spine protocol). Anesthesia will be standardized and include propofol for induction, a propofol and remifentanil infusion for maintenance (plus sevoflurane), and IV acetaminophen 1000 mg during the last 60 minutes of the case. On arrival to the postanesthesia care unit (PACU), patients will be assessed for pain by PACU nurses per standard protocols. Patients will be evaluated for pain on PACU arrival and then every 15 minutes. Patients will be administered hydromorphone 0.25-0.5 mg for pain, and doses will be repeated until the patient is comfortable (pain \< 3 on a scale of 0-10; 0=no pain and 10=worst pain imaginable). The patient will then be connected to a PCA device to deliver pain medication during the remainder of the postoperative period. All postoperative management will be per standard surgical protocols Sample Size: The primary end-point of the investigation is amount of hydromorphone used. In a clinical trial by Urban et al. of patients undergoing complex spine surgery using a standard anesthetic, average hydromorphone consumption in the first 24 hours was 27 mg (18). The investigators expect to see at least a 33% reduction in hydromorphone consumption in the methadone group. Group sample sizes of 39 and 39 achieve 91% power to detect a difference of 9.0 between the null hypothesis that both group means are 27.0 and the alternative hypothesis that the mean of group 2 is 18.0 with estimated group standard deviations of 10.0 and 10.0 and with a significance level (alpha) of 0.01000 using a two-sided two-sample t-test. The investigators plan to enroll a total of 100 patients to ensure complete collection of data.

Interventions

DRUGMethadone

Methadone 0.2 mg/kg administered at induction of anesthesia

DRUGHydromorphone

Hydromorphone 2 mg administered at the conclusion of anesthesia

Sponsors

Endeavor Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* All patients presenting for elective posterior lumbar or thoracic spinal fusion surgery will be eligible for enrollment.

Exclusion criteria

1. Preoperative renal failure (defined as a serum creatinine \> 2.0 mg/dL.) 2. American Society of Anesthesiologists Physical Status IV or V 3. Pulmonary disease necessitating home oxygen therapy 4. Allergy to methadone or hydromorphone 5. Preoperative recent history of opioid or alcohol abuse 6. Inability to use a PCA device or speak the English language

Design outcomes

Primary

MeasureTime frame
Hydromorphone Use at 24 HoursUse of hydromorphone at 24 hours

Secondary

MeasureTime frameDescription
Hydromorphone Use Third 24 Hours48-72 hours after surgery
Pain Scores Postanesthesia Care Unit (PACU) ArrivalFirst 5 minutes after PACU arrival11-point verbal rating scale (0=no pain, 10=worst pain imaginable)
Pain Scores 1 Hour After PACU ArrivalPain scores at 60 minutes after PACU admission11-point verbal rating scale (0=no pain, 10=worst pain imaginable)
Pain Scores 2 Hours After PACU ArrivalPain scores at 120 minutes after PACU admission11-point verbal rating scale (0=no pain, 10=worst pain imaginable)
Pain Scores on Postoperative Day OnePain scores one day after PACU admission11-point verbal rating scale (0=no pain, 10=worst pain imaginable)
Hydromorphone Use Second 24 Hours24-48 hours after surgery
Pain Scores Postoperative Day 3Pain scores 72 hours after PACU admission11-point verbal rating scale (0=no pain, 10=worst pain imaginable)
Patient Satisfaction ScoresPostopertive day 1Patient satisfaction with overall pain management will be determined using a 101-point verbal rating scale (0=highly dissatisfied (worst), 100=highly satisfied (best))
Chronic Persistent Surgical Pain-Weekly Frequency of PainOne month after surgery0=\< once per week; 1=once per week; 2=twice per week; 3=daily; 4=constant
Chronic Persistent Surgical Pain-weekly Frequency of Pain3 months after surgery0=\< once per week; 1=once per week; 2=twice per week; 3=daily; 4=constant
Pain Scores on Postoperative Day 2Pain scores 48 hours after PACU admission11-point verbal rating scale (0=no pain, 10=worst pain imaginable)

Countries

United States

Participant flow

Participants by arm

ArmCount
Methadone Group
Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose) Methadone: Methadone 0.2 mg/kg administered at induction of anesthesia
62
Hydromorphone Group
Patients will receive hydromorphone 2 mg at the end of the surgical procedure Hydromorphone: Hydromorphone 2 mg administered at the conclusion of anesthesia
53
Total115

Baseline characteristics

CharacteristicHydromorphone GroupMethadone GroupTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
19 Participants22 Participants41 Participants
Age, Categorical
Between 18 and 65 years
34 Participants40 Participants74 Participants
Age, Continuous60 years64.5 years62 years
Region of Enrollment
United States
53 participants62 participants115 participants
Sex: Female, Male
Female
32 Participants30 Participants62 Participants
Sex: Female, Male
Male
21 Participants32 Participants53 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 620 / 53
serious
Total, serious adverse events
0 / 620 / 53

Outcome results

Primary

Hydromorphone Use at 24 Hours

Time frame: Use of hydromorphone at 24 hours

ArmMeasureValue (MEDIAN)
Methadone GroupHydromorphone Use at 24 Hours4.56 milligrams
Hydromorphone GroupHydromorphone Use at 24 Hours9.9 milligrams
Secondary

Chronic Persistent Surgical Pain-weekly Frequency of Pain

0=\< once per week; 1=once per week; 2=twice per week; 3=daily; 4=constant

Time frame: 3 months after surgery

Population: A home postal survey was sent to participants in the clinical trial 3 months after surgery. 38 patients in the methadone group and 27 patients in the hydromorphone group returned the surveys.

ArmMeasureValue (MEDIAN)
Methadone GroupChronic Persistent Surgical Pain-weekly Frequency of Pain0 score on a scale
Hydromorphone GroupChronic Persistent Surgical Pain-weekly Frequency of Pain3 score on a scale
Secondary

Chronic Persistent Surgical Pain-Weekly Frequency of Pain

0=\< once per week; 1=once per week; 2=twice per week; 3=daily; 4=constant

Time frame: 12 months after surgery

Population: A home postal survey was sent to participants in the clinical trial 12 months after surgery. 39 patients in the methadone group and 40 patients in the hydromorphone group returned the surveys

ArmMeasureValue (MEDIAN)
Methadone GroupChronic Persistent Surgical Pain-Weekly Frequency of Pain0 score on a scale
Hydromorphone GroupChronic Persistent Surgical Pain-Weekly Frequency of Pain2 score on a scale
Secondary

Chronic Persistent Surgical Pain-Weekly Frequency of Pain

0=\< once per week; 1=once per week; 2=twice per week; 3=daily; 4=constant

Time frame: One month after surgery

Population: A home postal survey was sent to participants in the clinical trial 1 month after surgery. 41 patients in the methadone group and 34 patients in the hydromorphone group returned the surveys

ArmMeasureValue (MEDIAN)
Methadone GroupChronic Persistent Surgical Pain-Weekly Frequency of Pain2 score on a scale
Hydromorphone GroupChronic Persistent Surgical Pain-Weekly Frequency of Pain3 score on a scale
Secondary

Chronic Persistent Surgical Pain-Weekly Frequency of Pain

0=\< once per week; 1=once per week; 2=twice per week; 3=daily; 4=constant

Time frame: 6 months after surgery

Population: A home postal survey was sent to participants in the clinical trial 6 months after surgery. 24 patients in the methadone group and 32 patients in the hydromorphone group returned the surveys

ArmMeasureValue (MEDIAN)
Methadone GroupChronic Persistent Surgical Pain-Weekly Frequency of Pain0 score on a scale
Hydromorphone GroupChronic Persistent Surgical Pain-Weekly Frequency of Pain2 score on a scale
Secondary

Hydromorphone Use Second 24 Hours

Time frame: 24-48 hours after surgery

ArmMeasureValue (MEDIAN)
Methadone GroupHydromorphone Use Second 24 Hours0.6 milligrams
Hydromorphone GroupHydromorphone Use Second 24 Hours3.15 milligrams
Secondary

Hydromorphone Use Third 24 Hours

Time frame: 48-72 hours after surgery

ArmMeasureValue (MEDIAN)
Methadone GroupHydromorphone Use Third 24 Hours0 milligrams
Hydromorphone GroupHydromorphone Use Third 24 Hours0.35 milligrams
Secondary

Pain Scores 1 Hour After PACU Arrival

11-point verbal rating scale (0=no pain, 10=worst pain imaginable)

Time frame: Pain scores at 60 minutes after PACU admission

ArmMeasureValue (MEDIAN)
Methadone GroupPain Scores 1 Hour After PACU Arrival4 units on a scale
Hydromorphone GroupPain Scores 1 Hour After PACU Arrival6 units on a scale
Secondary

Pain Scores 2 Hours After PACU Arrival

11-point verbal rating scale (0=no pain, 10=worst pain imaginable)

Time frame: Pain scores at 120 minutes after PACU admission

ArmMeasureValue (MEDIAN)
Methadone GroupPain Scores 2 Hours After PACU Arrival4 units on a scale
Hydromorphone GroupPain Scores 2 Hours After PACU Arrival6 units on a scale
Secondary

Pain Scores on Postoperative Day 2

11-point verbal rating scale (0=no pain, 10=worst pain imaginable)

Time frame: Pain scores 48 hours after PACU admission

ArmMeasureValue (MEDIAN)
Methadone GroupPain Scores on Postoperative Day 24.56 units on a scale
Hydromorphone GroupPain Scores on Postoperative Day 26 units on a scale
Secondary

Pain Scores on Postoperative Day One

11-point verbal rating scale (0=no pain, 10=worst pain imaginable)

Time frame: Pain scores one day after PACU admission

ArmMeasureValue (MEDIAN)
Methadone GroupPain Scores on Postoperative Day One4 units on a scale
Hydromorphone GroupPain Scores on Postoperative Day One5 units on a scale
Secondary

Pain Scores Postanesthesia Care Unit (PACU) Arrival

11-point verbal rating scale (0=no pain, 10=worst pain imaginable)

Time frame: First 5 minutes after PACU arrival

ArmMeasureValue (MEDIAN)
Methadone GroupPain Scores Postanesthesia Care Unit (PACU) Arrival5 units on a scale
Hydromorphone GroupPain Scores Postanesthesia Care Unit (PACU) Arrival8 units on a scale
Secondary

Pain Scores Postoperative Day 3

11-point verbal rating scale (0=no pain, 10=worst pain imaginable)

Time frame: Pain scores 72 hours after PACU admission

ArmMeasureValue (MEDIAN)
Methadone GroupPain Scores Postoperative Day 34 units on a scale
Hydromorphone GroupPain Scores Postoperative Day 35 units on a scale
Secondary

Patient Satisfaction Scores

Patient satisfaction with overall pain management will be determined using a 101-point verbal rating scale (0=highly dissatisfied (worst), 100=highly satisfied (best))

Time frame: Postopertive day 1

ArmMeasureValue (MEDIAN)
Methadone GroupPatient Satisfaction Scores92.5 units on a scale
Hydromorphone GroupPatient Satisfaction Scores80 units on a scale
Secondary

Patient Satisfaction Scores

Patient satisfaction with overall pain management will be determined using a 101-point verbal rating scale (0=highly dissatisfied (worst), 100=highly satisfied (best))

Time frame: Postoperative day 3

ArmMeasureValue (MEDIAN)
Methadone GroupPatient Satisfaction Scores95 units on a scale
Hydromorphone GroupPatient Satisfaction Scores90 units on a scale
Secondary

Patient Satisfaction Scores

Patient satisfaction with overall pain management will be determined using a 101-point verbal rating scale (0=highly dissatisfied (worst), 100=highly satisfied (best))

Time frame: postoperative day 2

ArmMeasureValue (MEDIAN)
Methadone GroupPatient Satisfaction Scores90 units on a scale
Hydromorphone GroupPatient Satisfaction Scores82.5 units on a scale

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026